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Background and purpose: Perampanel, a selective noncompetitive antagonist at the 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is highly effective 
in a wide range of experimental models. Although initially licensed as adjunctive therapy for 
partial seizures with or without secondary generalization in patients aged 12 years or older, the 
US Food and Drug Administration has recently approved its use in the treatment of primary 
generalized tonic–clonic seizures (PGTCS). This paper reviews the pharmacokinetics, efficacy, 
and tolerability of perampanel as an antiepileptic drug.
Results: After oral ingestion, perampanel is rapidly absorbed (T
max
, 0.5–2.5 hours), has a bio-
availability of ~100%, and is highly protein bound (~95%) in plasma. It undergoes extensive 
(.90%) hepatic metabolism, primarily via cytochrome P450 3A4 (CYP3A4), with a half-life of 
48 hours. Carbamazepine and other antiepileptic drugs can enhance its metabolism via induction 
of CYP3A4. Efficacy of perampanel in focal seizures has been extensively evaluated in Phase II 
and randomized, placebo-controlled Phase III trials. The efficacy in PGTCS has been reported 
in one class I study. In the treatment of focal seizures, perampanel showed significant dose-
dependent median seizure reductions: 4 mg/d, 23%; 8 mg/d, 26%–31%; 12 mg/d, 18%–35%; 
and placebo, 10%–21%. The 50% responder rates were 15%–26%, 29%, 33%–38%, and 
34%–36% for placebo, 4 mg/d, 8 mg/d, and 12 mg/d perampanel, respectively. Freedom from 
seizures was recorded in 0%–1.7% of the placebo group, 1.9% of the 2 mg group, 2.6%–4.4% 
of the 8 mg group, and 2.6%–6.5% of the 12 mg group. For PGTCS, the median seizure reduc-
tion was 76.5% for perampanel and 38.4% for placebo. The 50% responder rate was 64.2% for 
perampanel and 39.5% for placebo. Seizure freedom during maintenance phase was 30.9% for 
perampanel and 12.3% for placebo. Adverse effects included dose-dependent increases in the 
frequency of dizziness, somnolence, fatigue, irritability, falls, and probably nausea.
Conclusion: Perampanel is effective in treating both partial-onset seizures and PGTCS.
Keywords: perampanel, new antiepileptic drug, epilepsy, primary generalized seizures, 
pharmacokinetics
Introduction
The number of antiepileptic drugs (AEDs) with specific efficacy in primary generalized 
tonic–clonic seizures (PGTCS) is limited. The majority of AEDs have been developed 
for treating focal seizures, with or without secondary generalization. Although some 
of these, eg, carbamazepine, are also licensed for treating generalized tonic–clonic 
seizures, it is possible that the seizures that respond to such AEDs are actually of focal 
onset. An indication that this might be the case is that seizure control tends to deterio-
rate when carbamazepine is prescribed for the classic generalized epilepsy, namely 
juvenile myoclonic epilepsy. The AEDs that fulfill the criterion of treating tonic–clonic 
seizures in juvenile myoclonic epilepsy include sodium valproate, lamotrigine, and 
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levetiracetam. The benzodiazepine drugs may also be effec-
tive but are not usually prescribed because of problems with 
tolerance and adverse effects. There is a need for additional 
AEDs that treat PGTCS. In this paper, we review the mode 
of action, pharmacokinetics, efficacy, and adverse effects of 
the new AED perampanel in patients with focal seizures and 
in patients with PGTCS.
Perampanel mode of action
in vitro studies
In vitro studies have shown that perampanel is a selective, non-
competitive antagonist at the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor.1,2 In studies in 
rat cortical neurons, perampanel has been shown to potently 
inhibit AMPA-evoked calcium currents (IC
50
 =93 nM [con-
centration of inhibitor where response is reduced by 50%]) 
compared with GYKI52466, which is a noncompetitive 
AMPA receptor antagonist (IC
50
 =12.5 µM).3 Furthermore, rat 
hippocampal slice studies show that perampanel is selectively 
active on AMPA receptors over other receptors.4 Indeed, 
perampanel has no effect on responses mediated by N-methyl-
d-aspartate (NMDA) receptors or kainate receptors.4
Efficacy of perampanel in animal seizure 
models
Perampanel is effective in various seizure models, including 
the mouse tonic–clonic generalized seizure model, the audio-
genic and maximal electric shock-induced seizure tests, and 
the pentylenetetrazole-induced seizure model. Perampanel 
also inhibits 6 Hz electroshock-induced seizures but is inac-
tive in genetic absence epilepsy rats from Strasbourg.3
Perampanel pharmacokinetic 
characteristics
The therapeutic effect of a drug in terms of dosing frequency 
is critically determined by its pharmacokinetic characteristics, 
which influence the recommended rate of dose titration, the 
time course of achieving an optimum therapeutic response, 
and patient compliance. Furthermore, because all new AEDs 
are licensed, at least initially, as adjunctive therapy, knowl-
edge of their propensity to interact with concomitant drugs is 
important.5,6 Successful therapy or failure will be determined 
not only by efficacy but also by these considerations.
Absorption and distribution
After oral ingestion, perampanel is rapidly absorbed (time to 
maximum concentration [T
max
], 0.5–2.5 hours), is not subject 
to any significant first-pass metabolism, and has a bioavail-
ability of almost 100%. It is highly protein bound (~95%) in 
plasma, primarily to albumin, and has a volume of distribution 
of 1.1 L/kg in adults. Co-ingestion with food delays the rate of 
absorption (maximum concentration [C
max
] values are decreased 
by 40%; T
max
 is delayed by 2 hours), but it does not affect the 
extent of absorption. In healthy individuals and patients with 
epilepsy, perampanel demonstrates linear pharmacokinetics 
over the dose range of 2–12 mg/d and the time to steady state 
is 10–19 days.7
Metabolism
Perampanel undergoes extensive hepatic metabolism 
(.90%) to form 13 major metabolites of hydroxylated 
perampanel and various glucuronide conjugates, none 
of which are pharmacologically active. The isoen-
zyme CYP3A4 is primarily considered to be involved in 
the metabolism of perampanel, although CYP3A5 may 
also contribute.7
elimination
The calculated mean plasma half-life of single-dose per-
ampanel in healthy adult volunteers is 48 hours. In the 
presence of enzyme-inducing AEDs (eg, carbamazepine), 
perampanel half-life values can decrease to ~25 hours. 
Only ~2% of an administered perampanel dose is excreted 
as unchanged perampanel in urine, while 70% of a dose is 
excreted in feces.7
Drug interaction profile
Perampanel is not expected to cause pharmacokinetic interac-
tions, because, at clinically relevant concentrations, in vitro, 
it is neither a potent inhibitor nor an inducer of cytochrome 
P450 (CYP) isoenzymes or uridine diphosphate glucurono-
syltransferases. However, perampanel will be the target of 
drug interactions, because CYP3A4, the principal isoen-
zyme responsible for its metabolism, is readily induced and 
inhibited.7 Concomitant AEDs that are CYP3A4 inducers (eg, 
carbamazepine, oxcarbazepine, phenytoin, and topiramate) 
will increase perampanel clearance and decrease peram-
panel plasma concentrations. Conversely, strong inhibitors 
of CYP3A4 (eg, ketoconazole) will decrease perampanel 
clearance and increase perampanel plasma concentrations. 
Although perampanel does not interact with combined oral 
contraceptives (when dosed at #8 mg/d), perampanel at 
12 mg decreases the concentration of levonorgestrel and 
could possibly compromise contraceptive control.
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Efficacy of perampanel in human 
studies
Partial seizures with or without 
secondary generalization
The efficacy of perampanel has been extensively evalu-
ated in various Phase II,8 randomized placebo-controlled 
Phase III,9–11 and open-label extension trials,12 as well as 
in postmarketing observational studies.13,14 Furthermore, 
pooled analysis of the five Phase II/Phase III trials has been 
undertaken.15,16 Patients recruited were $12 years of age, 
had refractory partial seizures with or without secondary 
generalization, and were on 1–3 additional AEDs.
The Phase III studies showed dose-dependent, statisti-
cally significant median seizure reductions: 4 mg/d, 23%; 
8 mg/d, 26%–31%; 12 mg/d, 18%–35%; and placebo, 
10%–21%.9–11 Perampanel 2 mg/d was not associated with 
any significant seizure reduction. The 50% responder rates 
were 15%–26%, 29%, 33%–38%, and 34%–36% for placebo, 
4, 8, and 12 mg/d perampanel, respectively. Freedom from 
seizures was recorded in 0%–1.7% of the placebo group, 
1.9% of the 2 mg group, 2.6%–4.4% of the 8 mg group, and 
2.6%–6.5% of the 12 mg group. Pooled analysis of these 
data confirmed the significant efficacy of perampanel, with 
median seizure reduction rates of 23.3%, 28.8%, and 27.2% 
for 4, 8, and 12 mg/d, respectively; the placebo effect was 
12.8%.15,16 Perampanel at a dose of 12 mg/d did result in 
improved efficacy in some patients.17 Analysis of the pooled 
data suggested that perampanel had efficacy against second-
arily generalized tonic–clonic seizures.18
Since perampanel was licensed for clinical use, its effi-
cacy has been further characterized from reports describing 
its use in everyday clinical practice13,14 and also from an open-
label extension study of the core Phase III studies.12 The study 
by Steinhoff et al13 included 74 patients (43 females) aged 
15–71 years (mean age: 38.4 years) who were followed up for 
6–7 months. Perampanel was administered in an initial dose 
of 2 mg/d for 14 days followed up by a 4 mg/d dose for a fur-
ther 4 weeks. Subsequently, the perampanel dose was titrated 
to a maximum individual tolerated dose; one patient achieved 
a dose of 14 mg/d. Comparing the last 3 months of observa-
tion to baseline revealed that 34 patients (46%) responded to 
treatment with at least a 50% reduction in seizure frequency. 
Of the 34 patients, ten became seizure free. Of the 43 patients 
co-prescribed enzyme-inducing AEDs, 18 patients (42%) 
responded to treatment, compared with 48% (15 patients) who 
were responders but were not co-prescribed enzyme-inducing 
AEDs. A subsequent multicenter study, which used the same 
study design but included 281 patients (152 females) with a 
mean age of 39 years (range: 12–84 years), reported similar 
findings.14 At the end of a 6-month follow-up, retention was 
60%; 50% of patients had at least a 50% reduction in seizure 
frequency.
The open-label extension study described by Montouris 
et al12 included 1,281 patients (50% females) with a median 
age of 33 years (range: 12–76 years). During the first 
16 weeks, patients who were already taking perampanel 
during one of the Phase III clinical trials continued to do so 
blinded, but if they were not already receiving 12 mg/d the 
dose was titrated to 12 mg/d or up to the maximally toler-
ated individual dose. For patients who had initially been 
randomized to placebo in the Phase III studies, perampanel 
was titrated during a 16-week period. After an initial dose 
of 2 mg/d, perampanel was increased by 2 mg/d every 
14 days up to a target dose of 10–12 mg/d. After a 52-week 
follow-up, mean seizure frequency decreased from baseline 
by 55% and 53.9% in the initial placebo and perampanel 
groups, respectively. Furthermore, the 50% responder rates 
were 55% and 52.8%, respectively.
Shah et al17 recently published a pooled, retrospective, 
case-note data study of 310 adult patients (mean age, 
40.9 years; range: 18–75 years; 50% females; 27.7% intel-
lectual disability). Only eight patients were said to have 
idiopathic generalized epilepsy. A total of 161 patients were 
treated for 6 months or longer. The 50% responder rates 
in the 3 months before the last follow-up were 57.5% for 
tonic–clonic seizures, 74% for complex partial (dyscognitive) 
seizures, and 14% for simple partial seizures. Adverse events 
were recorded in 209 patients (67.4%), and, of these, 67% 
withdrew from the perampanel because of adverse events. 
The most common adverse events were sedation 23.8%, 
behavioral/mood disturbance 22.6%, dizziness 13.5%, 
unsteadiness 11.3%, and increase in seizure frequency 7.1%. 
There was a significant increase in the prevalence of dizzi-
ness with fast titration, increasing the dose by .2 mg/2 wks 
(P=0.025). The authors drew attention to the high rate of 
irritability/aggression: 18.1%; in addition, 7.7% had mood 
change/anxiety. The rate of behavioral disturbance was much 
higher than that of 4.9% (aggression/irritability) reported by 
Steinhoff et al in the German/Austrian study,14 or the 1.6% 
(aggression) reported in the pooled analysis of the Phase III 
studies.16 The retention rate fell from 86% at 3 months to 27% 
at 18 months. The efficacy and adverse event results for the 
subgroup with intellectual disability were similar to those 
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1218
Besag and Patsalos
for the whole group, but simple partial seizures were not 
assessed because of difficulty in recording these accurately 
in this group.
The first pediatric use of perampanel has been reported 
in a series of 58 patients (32 females) with a mean age of 
10.5±4.2 years (range: 2–17 years).19 Although perampanel 
was usually started at 2 mg/d and titrated by 2 mg/wk or 
2 mg/2 wks, 1 mg dose steps and slower titration rates were 
used in children #12 years. After 3 months of perampanel 
therapy, 18 patients (31%) exhibited a 50% response rate 
and five patients (9%) became seizure free.
An audit of perampanel use in 47 patients (24 females; 
median age, 31 years; range: 18–61) attending a regional 
epilepsy service revealed a 50% responder rate of 28%, with 
21 patients (45%) withdrawing from perampanel treatment.20 
The dosing strategy was that typically employed for peram-
panel, namely 2 mg/d initially, increased by 2 mg/d every 
14 days.
Primary generalized seizures
There is a single published study of the efficacy and toler-
ability of perampanel in primary generalized epilepsy.21 This 
was an international, parallel-group, multicentre, double-
blind study in patients 12 years of age or older. It provided 
class I evidence of efficacy compared with placebo. A total of 
164 patients were randomized, of whom 162 were included 
in the full analysis: 81 treated with placebo and 81 with 
perampanel.
The investigators paid particular attention to the correct 
diagnosis of established “idiopathic” generalized epilepsy; 
a large proportion of the patients initially submitted were 
excluded on the basis of this reassessment. The “randomiza-
tion phase” included titration over weeks 1–4, maintenance 
over weeks 5–17, and follow-up (only for patients not 
entering an extension phase) over weeks 18–21. The active 
perampanel and the placebo were packaged and labeled so 
as to be indistinguishable. The initial perampanel dose was 
2 mg. The dose was increased in increments of 2 mg to a tar-
get dose of 8 mg or to the highest tolerated dose, whichever 
was lower. The final dose achieved during this phase was 
continued in the maintenance phase. Alteration of the dose 
was “not recommended” during the maintenance phase, but 
patients with inadequate seizure control could have the dose 
increased by one 2 mg increment (but not .8 mg) or patients 
with intolerable adverse events could have a dose reduction 
by one 2 mg increment. Seizure counts were recorded in 
patient diaries. The primary efficacy endpoint was the per-
centage change in PGTCS frequency per 28 days, including 
both the titration and maintenance phases, compared with 
the baseline. The secondary efficacy endpoint was the per-
centage of patients with a reduction in PGTCS of 50% or 
more (the responder rate). “Exploratory” efficacy endpoints 
included the rate of freedom from PGTCS, the rate of free-
dom from all seizures during the maintenance phase, and the 
investigator-assessed Clinical Global Impression of Change, 
rated on a scale from 1 (very much improved) to 7 (very much 
worse) – last observation was carried forward throughout the 
4 weeks before week 12. Biochemical, hematological, and 
urinalysis tests were performed. Vital signs and treatment-
emergent adverse events were recorded. The efficacy results 
were as follows. Median percentage change in PGTCS per 
28 days: perampanel −76.5%; placebo −38.4%; P,0.0001. 
PGTCS responder rate: perampanel 64.2%; placebo 39.5%; 
P=0.0019. Seizure freedom during maintenance phase: 
perampanel 30.9%; placebo 12.3%. The tolerability results 
were as follows. In each case, the treatment-emergent adverse 
events for perampanel were stated and the figure for placebo 
appears in parenthesis: any treatment-emergent adverse event 
82.7% (72.0%), dizziness 32.1% (6.1%), fatigue 14.8% 
(6.1%), headache 12.3% (9.8%), somnolence 11.1% (3.7%), 
irritability 11.1% (2.4%), nasopharyngitis 8.6% (8.5%), 
vertigo 8.6% (2.4%), vomiting 8.6% (2.4%), weight increased 
7.4% (3.7%), and nausea 6.2% (4.9%). The authors concluded 
that the most frequent treatment-emergent adverse events 
with perampanel were dizziness (32.1%) and fatigue (14.8%). 
However, it is difficult to draw any meaningful conclusions 
with regard to adverse effects from these relatively small 
numbers. Furthermore, no definitive conclusions can be drawn 
with regard to safety from the relatively small numbers treated 
in this trial or, indeed, from the total number treated in all the 
published clinical trials so far. Much larger numbers would 
be required. The authors concluded that their study provided 
class I evidence that adjunctive perampanel decreases PGTCS 
frequency compared with placebo in drug-resistant patients.
There are two case reports on the efficacy of perampanel 
in PGTCS in progressive myoclonus epilepsy. Schorlemmer 
et al22 described a case of a 21-year-old woman with progres-
sive myoclonus epilepsy (Lafora body disease), confirmed by 
the identification of a mutation in the EPM2A gene, who had a 
sustained remission of myoclonus and PGTCS with perampanel 
8 mg/d. When the dose was reduced to 6 mg/d, the seizures 
recurred, but when the dose was increased again to 10 mg the 
seizures stopped and she regained the ability to walk with the 
aid of a walker. Dirani et al23 described a 15-year-old girl with 
Lafora body disease and refractory epilepsy. Perampanel was 
titrated rapidly to 10 mg/d over a 12-day period. Approximately 
2 weeks after the perampanel was started, there was a marked 
improvement in both the myoclonus and the PGTCS frequency. 
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There was also a marked improvement in the activities of daily 
living. Her speech and motor skills improved, and her parents 
said that her memory also improved. She was able to eat and 
drink independently. She was discharged taking perampanel 
8 and 12 mg daily on alternate days.
Adverse effects
Distinguishing adverse effects from adverse events in clinical 
trials is subject to a number of confounding factors. Although 
the simplest approach to allow for these confounding factors 
is to compare the rate of adverse events in the perampanel-
treated group with the placebo-treated group, such grouped 
data do not allow for variables such as drug dosage, con-
comitant medication, and individual patient characteristics. 
Different studies may also use different methods of assessing 
adverse events. If allowance is made for such factors, there 
appears to be no obvious reason why the adverse effects of 
perampanel used for treating partial-onset seizures should 
be any different from the adverse effects when it is used for 
treating primary generalized seizures. Using pooled data has 
the major advantage of providing large numbers; for this 
reason, the pooled data from studies in partial-onset seizures 
have been compared with the data from the single study on 
PGTCS. A large pooled dataset on perampanel for the treat-
ment of partial-onset seizures is available from Montouris 
et al.12 In their analysis, 838 patients received perampanel 
during the core studies and continued with perampanel treat-
ment during the extension studies. The most common adverse 
events (greater than 10%) were as follows: dizziness 47.5%, 
somnolence 22.4%, headache 22%, fatigue 14.1%, weight 
increased 10.5%, nasopharyngitis 10.3%. However, these 
figures do not control for placebo effects. The data from the 
study by French et al21 on PGTCS do allow a comparison with 
placebo. The most common adverse events (again, greater 
than 10%) compared with the placebo rates (in parenthesis) 
were as follows: dizziness 32.1% (6.1%), fatigue 14.8% 
(6.1%), headache 12.3% (9.8%), somnolence 11.1% (3.7%), 
irritability 11.1% (2.4%). Taken together, and allowing for 
placebo effects, it would appear from these data that dizzi-
ness, fatigue, somnolence, and irritability are likely to be 
not only adverse events but adverse effects of perampanel, 
although further information from larger numbers of patients 
will be required before definitive statements can be made.
Another valuable way of providing information on 
adverse effects is to document the effect of dose on the rate 
of adverse events. If there is a clear relationship between 
the rate of an adverse event and the dose of the drug, it is 
highly likely that this is an adverse effect of the drug. Pooled 
data from three studies on partial-onset seizures, using 
information extracted from the tabulated summary provided 
by Rugg-Gunn,24 are shown in Figure 1.
This graph shows a clear relationship between dose and 
dizziness, somnolence, fatigue, irritability, falls, and probably 
nausea. The dose-relationship data highlight another issue 
which, although not surprising, is of clinical importance, 
namely that the rate of adverse effects is likely to be low if 
the perampanel dose is kept to a minimum. A recent analysis 
by Brodie et al (unpublished data, 2016) has indicated that 
the behavioral effects of perampanel, particularly aggression, 
appear to be dose related and are much less likely to occur 
at lower doses.
Conclusion
Although there is only one double-blind randomized 
controlled trial on the efficacy of perampanel in PGTCS, 
this appears to be a well-conducted study that provides 
unequivocal, highly statistically significant, class I evidence 
for efficacy. The tolerability of perampanel appears to be 
broadly similar to other AEDs; the most frequent adverse 
effects were dizziness and fatigue, although it should 
be noted that there have been reports of irritability and 
behavioral disturbance with higher doses than those used 
in this study. The total numbers of patients in reported trials 
remain too small to allow definitive statements to be made 
with regard to safety. On the basis of the current evidence, 
perampanel would appear to be a valuable addition to the 
available AEDs for the treatment of partial-onset seizures 
and to the limited choice available for the treatment of 
PGTCS. However, until it has been much more widely 
used in clinical practice, it will not be possible to determine 
what its final role in the treatment of patients with epilepsy 
will be.
Figure 1 Frequency of treatment-emergent adverse events for perampanel plotted 
against dose.
Note: The placebo results are plotted as 0 mg.
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